All the commercially available MGAs for ER+/HER2 − early breast cancer have been robustly clinically validated [8] and a plethora of studies consistently showed that their use can decrease chemotherapy recommendation in up to 50% of cases [9–17]. Here, ERBB2 is linked to breast carcinoma.